AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 8 - (NewsRx.com & NewsRx.net) -- The American College of Obstetricians and Gynecologists (ACOG) has announced the formation of a special Task Force on Hormone Replacement Therapy, a multispecialty panel of medical experts, to make clinical practice recommendations in light of the latest research findings on estrogen/progestin use in postmenopausal women.
Chairing ACOG's task force will be Isaac Schiff, MD, chair of the medical advisory board to ACOG's Managing Menopause magazine and the chief of the Vincent Memorial Obstetrics and Gynecology Service at Massachusetts General Hospital in Boston.
ACOG's task force, formed in June 2002, will expedite its research review and deliberations in light of recent study findings on the effect of combined estrogen and progestin therapy in women, including the July 9, 2002, announcement by the National Heart, Lung, and Blood Institute of the U.S. National Institutes of Health that it has stopped a major clinical trial on the risks and benefits of this combination therapy in healthy menopausal women. The trial was halted after 5.2 years of an 8-year study, due to an increased risk of invasive breast cancer.
The trial, a part of the Women's Health Initiative (WHI), also found small increases in coronary heart disease, stroke, and pulmonary embolism in study participants taking estrogen plus progestin (specifically, 0.625 conjugated estrogens plus 2.5 mg medroxyprogesterone acetate daily) compared with the placebo group. While the trial found benefits to the estrogen/progestin combination, including reduced rates of hip fracture and colon cancer, overall the harm was greater than the benefit of the hormone combination. The WHI trial on estrogen use alone is continuing, as study authors report no increased risk for breast cancer in the estrogen-only study group.
A full study report appeared in the July 17, 2002, issue of the Journal of the American Medical Association, and is also available on the journal's website at www.jama.com.
The WHI population study group was 16,608 healthy women ages 50-79. The data indicate that if 10,000 women take the hormone combination for 1 year, as compared with 10,000 women not taking the hormone combination:
* 8 more will ...
Source: HighBeam Research, ACOG issues statement on Estrogen Plus Progestin Trial of the Women's...